Q BioMed Announces Licensing Agreement
Q BioMed Inc. and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Under the terms of the agreement, Q Biomed receives global rights to develop and commercialize the drug in the rare pediatric disease market.
SteadyMed Raises $30 Million
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered into a definitive agreement to sell its ordinary shares and warrants to purchase its ordinary shares for aggregate gross proceeds of approximately $30 million in a private placement.
New Glatt GPCG 10 Fluid Bed Granulator at Metrics
Enhancing its known expertise in developing multi-particulate and modified-release drug products, Metrics Contract Services has acquired a new Glatt GPCG 10 fluid bed granulator with Wurster inserts.
Nemera Wins Editor's Choice Category at INTERPHEX Awards for Safelia®
International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral Drug Association (PDA), recently announced the winners for the INTERPHEX Exhibitor Awards for 2017.
Avomeen Analytical Services Announces New CEO
Avomeen Analytical Services, a full-service independent analytical testing and product development laboratory based in Ann Arbor, MI, recently announced that Mark Harvill has been named its CEO. High Street Capital of Chicago and Avomeen founder and retiring CEO Shri Thanedar, PhD, made the announcement.